Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline
(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage company pioneering AI-enabled drug discovery and development, reported third-quarter results ended September 30, 2026, reflecting a narrower net loss, positive REC-4881 data in familial adenomatous polyposis (FA